Antihypertensive therapy and insulin sensitivity: Do we have to redefine the role of β-blocking agents?

American Journal of Hypertension

Volumn 11, Issue 10 I, 1998, Pages 1258-1265

  Jacob, Stephan ^a   Rett, Kristian ^a   Henriksen, Erik J ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

Antihypertensive treatment; Cardiovascular disease; Carvedilol; Celiprolol; Dilevalol; Essential hypertension; Insulin sensitivity; Vasodilating blocker

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARVEDILOL; CELIPROLOL; CHOLESTEROL; DILEVALOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LIPOPROTEIN LIPASE; METOPROLOL; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE; PINDOLOL; PROPRANOLOL; TRIACYLGLYCEROL;

ANTIHYPERTENSIVE THERAPY; ATHEROGENESIS; CARBOHYDRATE METABOLISM; CEREBROVASCULAR ACCIDENT; DYSLIPIDEMIA; HUMAN; HYPERTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; ISCHEMIC HEART DISEASE; OXIDATIVE STRESS; PERIPHERAL CIRCULATION; PRIORITY JOURNAL; REVIEW; SYMPATHETIC NERVE; VASCULAR ENDOTHELIUM; VASCULAR RESISTANCE; WEIGHT GAIN;

EID: 0031767559     PISSN: 08957061     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0895-7061(98)00141-1     Document Type: Review

References (44)

1. Ferrannini E, Buzzigoli G, Bonadona R, et al: Insulin resistance in essential hypertension. N Engl J Med 1987; 317:350-357.
2. DeFronzo RA, Ferrannini E: Insulin resistance: a multi-faceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia. Diabetes Care 1991;14:173-177.
3. Collins R, Peto R, MacMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2: Short term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335:827-838.
4. Laffer CL, Elijovich F: Suboptimal outcome of management of metabolic cardiovascular risk factors in hispanic patients with essential hypertension. Hypertension 1995; 26(part 2):1079-1084.
5. Skarfors ET, Lithell HO, Selinus I, Aberg H: Do antihypertensive drugs precipitate diabetes in predisposed men? Br Med J 1989;298:1147-1152.
6. Samuelsson O, Hedner T, Berglund G, et al: Diabetes mellitus in treated hypertension: incidence, predictive factors and the impact of non-selective beta-blockers and thiazide diuretics during 15 years treatment of middle-aged hypertensive men in the primary prevention trial Göteborg, Sweden. J Human Hypertens 1994;8:257-263.
7. Mykkänen L, Kuusisto J, Pyörälä K, et al: Increased risk of non-insulin-dependent diabetes mellitus in elderly hypertensive subjects. J Hypertens 1994;12:1425-1432.
8. Black HR: The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990;15(suppl 5):S26-S38.
9. Grimm RH: Antihypertensive therapy: taking lipids into consideration. Am Heart J 1991;122:910-918.
10. Weber MA: Hypertension with concomitant conditions: the changing role of β-adrenoreceptor blockade. Am Heart J 1991;121:716-723.
11. Superko HR, Haskell WL, Krauss RM: Association of lipoprotein subclass distribution with use of selective and non-selective beta-blocker medications in patients with coronary heart disease. Arteriosclerosis 1993;101: 1-8.
12. Middeke M, Richter WO, Schwandt P, et al: Normalization of lipid metabolism after withdrawal from antihypertensive long-term therapy woth betablockers and diuretics. Arteriosclerosis 1990;10:145-147.
13. DeFronzo RA, Tobin JD, Andres R: Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-E223.
14. Pollare T, Lithell HO, Selinus I, Berne C: Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia 1988;31:415-420.
15. Pollare T, Lithell HO, Berne C: A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 1989;321:868-873.
16. Berne C, Pollare T, Lithell H: Effects of antihypertensives on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 1991;14(suppl 4):39-47.
17. Pollare T, Lithell H, Mörlin C, et al: Metabolic effects of diltiazem and atenolol: results from a randomized, double-blind study with parallel groups. J Hypertens 1989; 7:551-559.
18. Lind L, Berne C, Pollare T, Lithell H: Metabolic effect of isradipine as monotherapy or in combination with pindolol during long-term anti-hypertensive treatment. J Intern Med 1994;236:37-42.
19. Lind L, Berne C, Pollare T, Lithell H: Metabolic effects of anti-hypertensive treatment with nifedipine or furosemide: a double-blind, cross-over study. J Human Hypertens 1995;9:137-141.
20. Pollare T, Lithell HO, Selinus I, Berne C: Sensitivity to insulin during treatment with atenolol and metoprolol: a randomized, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 1989;298:1152-1157.
21. Lithell H, Pollare T, Vessby B: Metabolic effects of pindolol and propranolol in a double-blind cross-over study in hypertensive patients. Blood Pressure 1992;1: 92-101.
22. Haenni A, Lithell H: Treatment with a betablocker with β2-agonism improves glucose and lipid metabolism in essential hypertension. Metabolism 1994;43:455-461.
23. Jacob S, Rett K, Wicklmayr M, et al: Differential effect of chronic treatment with two betablocking agents on insulin sensitivity: the carvedilol-metoprolol study. J Hypertens 1996;14:489-494.
24. Harper R, Ennis CN, Heaney AP, et al: A comparison of the effects of low- and conventional-dose thiazide diuretic on insulin action in hypertensive patients with NIDDM. Diabetologia 1995;38:853-859.
25. Kiens B, Lithell H, Mikines KJ, Richter EA: Effects of insulin and exercise on muscle lipoprotein lipase activity in man and its relations to insulin action. J Clin Invest 1989;84:1124-1129.
26. Rabkin SW: Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993;33:286-291.
27. Rössner S, Taylor CL, Byington RP, Furberg CD: Long term propranolol treatment and changes in body weight after myocardial infarction. Brit Med J 1990;300:902-903.
28. Swislocki ALM: Impaired insulin clearance in essential hypertension. J Hum Hypertens 1994;8:185-190.
29. Laakso M, Edelman V, Brechtel G, Baron AD: Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. J Clin Invest 1990;85:1844-1852.
30. Rocchini AP, Moorehead C, Katch V, et al: Forearm resistance vessel abnormalities and insulin resistance in obese adolescents. Hypertension 1992;19:615-620.
31. Lind L, Lithell H: Decreased peripheral blood flow in the pathogenesis of the metabolic syndrome comprising hypertension, hyperlipidemia, and hyperinsulinemia. Am Heart J 1993;125:1494-1497.
32. Steinberg HO, Brechtel G, Johnson A, et al: Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994;94:1172-1179.
33. Julius S, Jamerson K: Sympathetics, insulin resistance and coronary risk in hypertension: the "chicken-and-egg" question. J Hypertens 1994;12:495-502.
34. Lembo G, Vecchione C, Iaccarino G, Trimarco B: The crosstalk between insulin and the sympathetic nervous system: possible implications in the pathogenesis of essential hypertension. Blood Pressure 1996;5(suppl 1):38-42.
35. Lund-Johansen P, Omvik P, Nordrehaug JE: Long-term hemodynamic effects of antihypertensive treatment. Clin Invest 1992;70:S58-S64.
36. Kodama J, Katayama S, Tanaka K, et al: Effect of captopril on glucose concentration. Possible role of augmented postprandial forearm blood flow. Diabetes Care 1990;13:1109-1111.
37. Eggertsen R, Sivertsson R, Andren L, Hansson L: Acute and long term hemodynamic effects of carvedilol, a combined beta-adrenoreceptor blocking and pre-capillary vasodilating agent, in hypertensive patients. J Cardiovasc Pharmacol 1987;10:S76-S80.
38. Malminiemi K: Association between serum lipids, glucose tolerance, and insulin sensitivity during 12 months of celiprolol treatment. Cardiovasc Drugs Therapy 1995; 9:295-304.
39. Hauf-Zachariou U, Widmann L, Zulsdorf B, et al: A double-blind comparison of the effects of carvedilol and captopril on serum lipid concentrations in patients with mild to moderate essential hypertension and dyslipidemia. Eur J Clin Pharmacol 1993;45(2):95-100.
40. Jacob S, Henriksen EJ, Fogt DL, et al: Celiprolol improves insulin-stimulated glucose transport actvity in skeletal muscle of obese Zucker rats (abst). Diabetologia 1996;39(suppl 1):289.
41. Feuerstein G, Yue TL, Ruffolo RR: Carvedilol update: a multiple action antihypertensive agent with antioxidant capacity and the potential for myocardial and vascular protection. Drugs of Today 1993;29:401-419.
42. Mehta JL, Lopez LM, Chen L, Cox OE: Alterations in nitric oxide synthase activity, superoxide anion generation, and platelet aggregation in systemic hypertension, and the effects of celiprolol. Am J Cardiol 1994;74:901-905.
43. Roesen P, Ballhausen T, Bloch W, Addicks K: Endothelial relaxation is disturbed by oxidative stress in the diabetic rat heart: influence of tocopherol as an antioxidant. Diabetologia 1995;38:1157-1168.
44. Paolisso G, Giugliano D: Oxidative stress and insulin action: is there a relationship? Diabetologia 1996;39:357-363.